YOLFTbeta
Beyond Air Inc

Beyond Air Inc

XAIR · NASDAQ · Healthcare / Medical Devices

2.13USD-0.08 (-3.40%)

Price History

Full chart

Market Stats

Previous Close2.21
Open2.24
Day Range2.00 – 2.24
52-Week Range2.38 – 55.60
Volume35.09K
Market Cap2.79M
P/E (TTM)0.00
Forward P/E0.00
EPS-65.82
Dividend Yield0.00%
Beta0.13
50-Day Avg4.56
200-Day Avg12.43

About

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Robert Scott Goodman
  • Employees54
  • Headquarters900 Stewart Avenue, Garden City, NY, United States, 11530, USA
  • Websitehttps://www.beyondair.net

Leadership

  • Mr. Robert Scott GoodmanCEO & Director · b. 1965
  • Mr. Daniel J. Moorhead CPAChief Financial Officer · b. 1972
  • Mr. Michael A. GaulChief Operating Officer · b. 1955
  • Mr. Denton DrewellPrincipal Accounting Officer & Controller · b. 1987
  • Dr. Andrew R. Colin M.D.Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board
  • Dr. John Jett Ph.D.Head of Research & Clinical Development
  • Mr. Amir AvnielChief Executive Officer of NeuroNOS · b. 1974
  • Mr. Adam T. NewmanCorporate Secretary

Financials

Income Statement

Currency: USD2014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Revenue---007.72M1.39M873.00K145.19K59.00K1.16M3.71M7.68M
Growth (%)-------82.00%-37.20%-83.37%-59.36%+1864.41%+219.67%+107.26%
Cost of Revenue----38.00K3.06M18.14M-588.00K555.00K2.47M5.37M7.43M
Gross Profit-----38.00K7.72M1.39M873.00K-588.00K-555.00K-1.31M-1.66M252.00K
Gross Margin-----100.00%100.00%100.00%-404.99%-940.68%-112.77%-44.89%3.28%
Operating Expense----11.03M10.78M19.53M23.09M40.12M51.50M61.70M42.87M29.30M
Operating Income-1.38M-2.16M-2.21M-29.29K-11.07M-3.06M-18.14M-22.21M-40.71M-52.06M-63.01M-44.54M-29.04M
Operating Margin------39.60%-1305.08%-2544.56%-28039.12%-88235.59%-5436.24%-1202.08%-378.23%
EBITDA-1.37M-2.14M-2.18M-4.29K-16.92M-6.49M-19.91M-22.02M-42.70M-58.20M-59.03M-41.89M-31.23M
EBITDA Margin------84.07%-1432.04%-2522.57%-29407.67%-98645.76%-5093.27%-1130.61%-406.75%
Net Income-1.65M-4.81M-3.66M-29.75K-18.04M-6.56M-19.94M-22.88M-43.18M-55.82M-60.24M-46.63M-33.25M
Net Income Margin------84.91%-1434.61%-2620.27%-29738.27%-94603.39%-5197.76%-1258.43%-432.99%
R&D898.00K1.17M1.62M673.00K4.44M3.93M10.65M12.62M11.80M16.81M24.36M16.86M10.24M
R&D as % of Total Revenue-----50.87%766.05%1445.36%8128.66%28491.53%2102.07%454.98%133.36%
Interest Expense--04621.06M1.51K30.54K642.00K775.00K30.00K2.91M3.02M3.52M
Interest Expense % of Total Revenue-----0.02%2.20%73.54%533.78%50.85%251.25%81.48%45.77%

Balance Sheet

Currency: USD2014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Assets193.00K498.00K5.94K5.94K9.36M9.43M27.43M40.52M99.20M68.75M56.96M30.06M35.38M
Total Liabilities425.00K1.58M31.10K31.10K7.81M5.40M9.34M10.06M20.99M26.72M29.77M15.72M29.18M
Total Equity-232.00K-1.08M-25.16K-25.16K1.54M4.02M18.09M30.46M78.21M42.03M25.05M13.58M6.13M
Cash23.00K331.00K5.92K5.92K732.54K1.34M19.83M34.63M80.24M29.16M11.38M4.67M6.74M
Total Debt22.00K997.00K30.00K2.92M33.12K263.60K4.88M6.93M9.41M5.77M17.84M11.69M23.38M
Net Debt-1.00K666.00K24.08K24.08K-699.42K-1.08M-14.95M-27.70M-76.75M-25.57M6.46M7.02M16.64M

Cash Flow

Currency: USD2014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Operating Cash Flow-804.00K-1.88M-1.66M-692.00K-7.12M1.34M-15.19M-19.64M-23.13M-33.01M-56.02M-38.22M-18.14M
Investing Cash Flow298.00K-18.00K-14.00K-1.15M-1.79M4.42M-890.00K-1.45M-20.59M-12.23M14.90M-3.67M
Financing Cash Flow362.00K2.04M1.63M556.00K9.46M1.07M34.88M30.33M79.45M2.70M43.17M16.65M29.09M
Capital Expenditure73.00K18.00K7.00K7.00K244.00K56.48K43.63K890.00K1.45M3.88M5.75M5.88M1.02M
Free Cash Flow-877.00K-1.90M-1.67M-692.00K-7.36M1.28M-15.24M-20.53M-24.58M-36.89M-61.76M-44.10M-19.17M
Dividends Paid------522.48K-11.14M----
FCF to OCF109.08%100.96%100.42%100.00%103.43%95.79%100.29%104.53%106.26%111.75%110.26%115.39%105.65%
Dividend Paid to FCF-------3.43%--45.31%----

Earnings

Report DateSep 30, 2016May 15, 2017Aug 11, 2017Nov 3, 2017Mar 19, 2018Jun 14, 2018Aug 14, 2018Nov 14, 2018Feb 13, 2019Jun 25, 2019Aug 14, 2019Nov 6, 2019Feb 7, 2020Jun 22, 2020Aug 6, 2020Nov 12, 2020Feb 9, 2021Jun 10, 2021Aug 10, 2021Nov 11, 2021Feb 10, 2022Jun 28, 2022Aug 11, 2022Nov 8, 2022Feb 10, 2023Jun 22, 2023Aug 15, 2023Nov 13, 2023Feb 12, 2024Jun 24, 2024Aug 6, 2024Nov 11, 2024Feb 10, 2025Jun 17, 2025Aug 12, 2025Nov 10, 2025Feb 13, 2026Jun 26, 2026Aug 13, 2026Nov 9, 2026
EPS Estimate---5.40-9.53-7.87-5.13-0.29-3.70-4.500.28-5.60-6.00-6.80-0.38-6.25-6.80-6.25-0.31-4.28-6.00-5.20-0.27-5.93-6.60-8.20-0.47-8.10-9.16-10.80-0.48-6.35-5.68-3.20-0.15-1.32-0.26-0.54-0.45-8.60-
EPS Actual-35.42-0.95-9.20-23.60-5.602.80-0.36-10.602.200.41-13.40-7.60-8.60-0.36-8.00-6.00-6.60-0.24-6.20-7.20-5.80-0.73-7.40-8.00-8.60-0.67-9.00-10.20-10.00-0.36-5.40-5.60-3.00-0.09-1.53-1.25-0.85-0.7711.00-
Surprise---70.37%-147.64%28.84%154.58%-24.14%-186.49%148.89%46.43%-139.29%-26.67%-26.47%5.26%-28.00%11.76%-5.60%22.58%-44.86%-20.00%-11.54%-170.37%-24.79%-21.21%-4.88%-42.55%-11.11%-11.35%7.41%25.00%14.96%1.41%6.25%40.00%-15.91%-380.77%-57.41%-71.11%227.91%-
Timing-Pre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap2.79M
Enterprise Value16.75M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.36
Price / Book1.48
EPS-65.82
Book Value2.69
Revenue (TTM)7.69M
Gross Profit (TTM)321.00K
EBITDA-24.80M
Profit Margin0.00%
Operating Margin-373.98%
Return on Equity-519.51%
Return on Assets-57.45%
Shares Outstanding984.41K
Shares Float852.14K
Beta0.13
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 5 analystsTarget 20.00
  • Strong Buy
    1
  • Buy
    3
  • Hold
    1

Ownership Breakdown

Institutions
7.00%
Insiders
11.22%
Retail / Other
81.78%

Top Institutional Holders

  • Balyasny Asset Management LLC
    464.16K2.36%
  • Murchinson Ltd.
    329.99K1.68%
  • Geode Capital Management, LLC
    159.44K0.81%
  • Daytona Street Capital LLC
    151.55K0.77%
  • Bleichroeder LP
    86.49K0.44%
  • Vanguard Capital Management, LLC
    31.94K0.16%
  • Vanguard Fiduciary Trust Co
    29.37K0.15%
  • Jane Street Group LLC
    27.52K0.14%
  • BlackRock Inc
    22.03K0.11%
  • WEALTH EFFECTS LLC
    16.96K0.09%
  • Baldwin Brothers Inc
    14.80K0.08%
  • XTX Topco Ltd
    12.06K0.06%
  • Virtu Financial LLC
    10.80K0.05%
  • Advisor Group Holdings, Inc.
    8.12K0.04%
  • Tower Research Capital LLC
    4.58K0.02%

Top Fund Holders

  • Tiger FR Offshore Equity A
    3.97K0.40%
  • Fidelity Extended Market Index
    2.92K0.30%
  • Fidelity Nasdaq Composite Index
    1.72K0.17%
  • Fidelity Total Market Index
    4060.04%
  • Fidelity Series Total Market Index
    3170.03%

Stock Splits

  • Jul 13, 20261:20
  • Jul 14, 20251:20